News Feb 13, 2025
Join Porton at Leading Industry Conferences to Explore Innovations and Network with Experts
Porton Pharma Solutions is thrilled to announce its participation in several major industry events across the globe during the first and second quarters of 2025. As a leading end-to-end integrated CDMO company, Porton boasts globally advanced technology platforms and extensive project delivery experience in small molecules, peptides and oligonucleotides, ADCs (including antibodies, payload-linkers, conjugation, and drug product filling), and Advanced Therapy Medicinal Products.
News Jan 28, 2025
Our Incredible Journey in 2024
Under open skies, the years pass endlessly. As the sun rises, Porton welcomes a new year with sincerity and hope. Reflecting on 2024, we faced challenges together, standing strong and united, achieving great heights.
News Jan 14, 2025
Successful GMP Drug Product Delivery by Porton Biologics and Conjugates Platform
Recently, the Porton Biologics and Conjugates Platform successfully completed the GMP contract manufacturing of three batches of sterile drug products for a client at our R&D and production facility in Pudong, Shanghai. This milestone marks a significant step forward for our Biologics and Conjugates CDMO platform—a testament to our unwavering commitment to quality and reliability.
News Jan 03, 2025
Porton Achieves Higher Scores in the 2024 S & P Global ESG Assessment
Porton Pharma Solutions Ltd. (hereinafter “Porton”) is glad to announce that it scored 44 (out of 100) in the 2024 S&P Global Corporate Sustainability Assessment reflecting an improvement of 6 points over the previous assessment, where scores in all the three dimensions getting improved. (CSA Score as of 27/11/2024).
News Dec 23, 2024
Porton Pharma Solutions and Dragon Sail Pharmaceutical Form Strategic Partnership
On December 20, 2024, Porton Pharma Solutions Ltd. (hereinafter referred to as “Porton Pharma Solutions” or “Porton”) and Dragon Sail Pharmaceutical (Shanghai) Co., Ltd. (a subsidiary of Guilin Sanjin, hereinafter referred to as “Dragon Sail Pharmaceutical”) formally signed a strategic cooperation agreement in Guilin, southern of China.
NewslettersDec 19, 2024
Porton Newsletter | Q4 2024 Recap
Porton Expands GMP Manufacturing and New Modality Services in Shanghai Fengxian Porton Successfully Hosts Ceremony for New Modality Capacity Upgrade Drug Modalities: Innovative Services & Solutions from Porton Pharma
News Dec 11, 2024
Porton and Aojin Collaborate to Advance XDC Drugs for Dual INDs
Recently, Porton Pharma Solutions Ltd. ("Porton") announced a strategic partnership with Aojin Life Sciences (Yixing) Co., Ltd. ("Aojin Life Sciences").
News Dec 06, 2024
Porton Recognized as an Exemplary Case for Sustainable Development
Porton was recently selected as a "2024 Exemplary Case for Sustainable Development Among Chinese Listed Companies" by the China Association of Public Companies.
News Dec 06, 2024
Porton is thrilled to announce the launch of its newly redesigned official website
With a Focus on Globalization, Innovative Technology Platforms, and Accelerating Your New Business Opportunities into the Clinic and to the Market.
